Estrogen Activation by Steroid Sulfatase Increases Colorectal Cancer Proliferation via GPER
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Context: Estrogens affect the incidence and progression of colorectal cancer (CRC), although the precise molecular mechanisms remain ill-defined. Objective: The present study investigated prereceptor estrogen metabolism through steroid sulphatase (STS) and 17β-hydroxysteroid dehydrogenase activity and subsequent nongenomic estrogen signaling in human CRC tissue, in The Cancer Genome Atlas colon adenocarcinoma data set, and in in vitro and in vivo CRC models. We aimed to define and therapeutically target pathways through which estrogens alter CRC proliferation and progression. Design, Setting, Patients, and Interventions: Human CRC samples with normal tissue-matched controls were collected from postmenopausal female and age-matched male patients. Estrogen metabolism enzymes and nongenomic downstream signaling pathways were determined. CRC cell lines were transfected with STS and cultured for in vitro and in vivo analysis. Estrogen metabolism was determined using an ultra-performance liquid chromatography–tandem mass spectrometry method. Primary Outcome Measure: The proliferative effects of estrogen metabolism were evaluated using 5-bromo-2′-deoxyuridine assays and CRC mouse xenograft studies. Results: Human CRC exhibits dysregulated estrogen metabolism, favoring estradiol synthesis. The activity of STS, the fundamental enzyme that activates conjugated estrogens, is significantly (P < 0.001) elevated in human CRC compared with matched controls. STS overexpression accelerates CRC proliferation in in vitro and in vivo models, with STS inhibition an effective treatment. We defined a G-protein–coupled estrogen receptor (GPER) proproliferative pathway potentially through increased expression of connective tissue growth factor in CRC. Conclusion: Human CRC favors estradiol synthesis to augment proliferation via GPER stimulation. Further research is required regarding whether estrogen replacement therapy should be used with caution in patients at high risk of developing CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Insights into the regulation of protein abundance from proteomic and transcriptomic analyses
Vogel, C., & Marcotte, E. M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3185 · Cited by 4,195
A transmembrane intracellular estrogen receptor mediates rapid cell signaling
Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B., & Prossnitz, E. R. (2005) · Science · doi:10.1126/science.1106943 · Cited by 2,302 · cited 1×
“However, no human CRC studies have examined the G-protein coupled estrogen receptor (GPER), an endo plasmic reticulum membrane-bound receptor with high E2-binding affinity (18) with known pro-proliferative actions in breast (19) and endometrial cancer (20).”
BackgroundEstrogen regulates Hippo signaling via GPER in breast cancer
Zhou, X., Wang, S., Wang, Z., Feng, X., Liu, P., Lv, X.-B., Li, F., Yu, F.-X., Sun, Y., Yuan, H., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79573 · Cited by 232
What have we learned about GPER function in physiology and disease from knockout mice
Prossnitz, E. R., & Hathaway, H. J. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2015.06.014 · Cited by 157 · cited 1×
“GPER deficiency results in multiple physiological a lterations including obesity, cardiovascular dysfunction, insulin resistance and glucose intolerance (37), and there is much interest in its pro-proliferative effects in breast cancer.”
Background
Cited by
The G protein-coupled oestrogen receptor GPER in health and disease: an update
Prossnitz, E. R., & Barton, M. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00822-7 · Cited by 231
Potter, B. V. L. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0045 · Cited by 73
Steroid sulphatase and its inhibitors: past, present, and future
Foster, P. A. (2021) · Molecules · doi:10.3390/molecules26102852 · Cited by 49
“No clinical trials have been conducted to examine STS inhibition in colorectal cancer despite promising pre-clinical studies in this area [62,72] Other conditions have also not been fully explored with regard to STS inhibition.”
BackgroundSelf-citation
Metadata
- Authors
- Gilligan, L. C., Rahman, H. P., Hewitt, A.-M., Sitch, A. J., Gondal, A., Arvaniti, A., Taylor, A. E., Read, M. L., Morton, D. G., & Foster, P. A.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2017-09-13
- Volume
- 102
- Issue
- 12
- Pages
- 4435-4447
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2754166255
- Cited by
- 46
- References
- 4
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.